Leadership
Dan Teleman
MSc, MBA - CEO
Dan Teleman has been Pharma Two B’s CEO since May 23 and was previously the company’s President and brings over 20 years of experience in the biotechnology industry. Dan also serves as a Board member of 4C Biomed, an early stage immune-oncology company developing a novel antibody. Prior to joining Pharma Two B, Dan was an Executive Partner at Israel Biotech Fund, a life science VC. Dan was Chairman of Tamarix Pharma, an early stage ophthalmology company developing novel anti apoptotic molecules. Prior to that, Dan was the CEO of Atox Bio, where he led the company through an NDA submission for Reltecimod, the first immunomodulator developed for NSTI. Previously, Dan was the co-founder and CEO of PainReform (Nasdaq: PRFX), head of business development for Pharmos (Nasdaq: PARS) and held marketing and sales roles at Amgen. Dan is experienced in company formation, growth and fund raising. Dan holds an MBA from Duke University, Fuqua School of Business, and an MSc in Biochemical engineering from the Ben Gurion University.
Pninit Litman
PhD - VP Clinical Operations
Dr. Litman, serves as Pharma Two B's head of pharmacology and clinical studies since 2008. Prior to this Dr. Litman served as head of biology at Develogen Israel LTD and Peptor LTD where she gained extensive experience in investigational new drug development. Dr. Litman received her B.Sc. in microbiology from the Hebrew University of Jerusalem , Ph.D. in neurobiology from Weizmann Institute of Science and completed her post-doctoral training at Stanford University Medical Center, in USA.
Irit Zalayet
CPA, M.A. in Law - CFO
Ms. Zalayet CPA serves as Pharma Two B’s CFO as of September 2010. Prior to this Ms. Zalayet served as deputy CEO of Kesselman & Kesselman Trust Co. (1971) Ltd. and as a CPA at PwC Israel. Irit completed her Bachelors in Economics and Accounting and her M.A. in Law; both degrees are from The Bar- Ilan University. Ms. Zalayet also serves as the CFO of Stem Cell Medicine.
Danny Fishelovitch
PhD - Head of CMC
Dr. Danny Fishelovitch has over 15 years of experience in the pharmaceutical industry. He Headed the Chemistry, Manufacturing and Controls (CMC) at several Biotech companies including Enlivex Therapeutics, Mitoconix Bio and Neuroderm that was acquired by Mitsubishi Tanabe Pharma group. Prior to that, Danny was a CMC leader and a lead formulator at Teva pharmaceuticals Ltd. Innovative R&D. Danny had also founded DFarma consulting and provides CMC consulting services for Biopharma companies. Danny specializes in the development of various sterile and solid dosage forms as well as drug device combination dealing with small molecules, Biopharmaceuticals such as peptides and proteins and cell based advanced therapeutic medicinal products (ATMPs). In addition, Danny has extensive experience in the development, scale-up and optimization of manufacturing processes by applying Quality-by-Design methodology. Danny was involved in clinical development plans (early POC to late-stage phase III) and in marketing regulatory applications. Danny is a pharmacist and computer scientist by training and holds a Ph.D. in Structural Biology from the Tel-Aviv University. He is an author of eight published scientific papers.
Cheryl Fitzer-Attas
PhD, MBA - Head of Medical Affairs
Dr. Cheryl Fitzer-Attas has >20 years of experience in the life sciences industry, with a clinical focus on neurological indications. Today, Cheryl is President of ClinMed LLC, where she works with several companies as Senior Advisor for clinical and medical affairs. Previously, Cheryl was Senior Medical Director at Mitsubishi Tanabe Pharma America, where she established the US and global medical affairs roadmaps for a new drug-device treatment for Parkinson’s disease. Before that, Cheryl was Vice President Clinical Research at CHDI, a not-for-profit research organization dedicated to acceleration of treatments for Huntington’s disease. Previously, at Teva Pharmaceuticals Industries, Cheryl was Global Medical Director for the Parkinson’s disease drug Azilect, where she played a pivotal role in the scientific communication of Azilect’s clinical trial data, including presentation and moderation at a public FDA Advisory Committee meeting. Dr. Fitzer-Attas has a B.Sc. in biology from the Hebrew University of Jerusalem, a Ph.D. in cell biology from the Weizmann Institute of Science, an MBA in marketing from Reichmann University, and she completed post-doctoral trainings at both the Weizmann Institute of Science and the University of California, San Francisco.
Hadas Friedman
MSc - VP Regulatory Affair & QA
Ms. Friedman serves as Pharma Two B’s VP QA, RA and Clinical Affairs since 2013. Prior to this Ms. Friedman served as the VP QA, RA and Clinical Affairs at Intec Pharma from 2004. Previous companies include Procognia and Rafa Laboratories. Hadas has completed a Bachelors of Science and a Masters of Science at the Bar-Ilan University.
Corinne Zollmann
PhD - CMC Consultant
Dr. Corinne Zollmann has over 30 years of experience in the pharmaceutical industry, and is currently supporting biotechnology companies by providing Chemistry, Manufacturing, and Controls (CMC) consulting services. Her prior roles include SVP of CMC at both Tamarix Pharma and at Atox Bio, where she was responsible for the CMC Modules of the Reltecimod NDA submission. Prior to that she served as Senior Director of CMC at Chiasma and spent more than 20 years in numerous leadership positions at Teva Pharmaceutical’s Global Innovative R&D Division, including as Director of the CMC Program for Small Molecules. During that time, she gained broad experience in global development of innovative pharmaceutical drug products, including CMC management and development, validation, technology transfer, risk management, regulatory strategy and initiatives, and professional CMC project evaluation and due diligence. Corinne holds a PhD in Electrochemistry from the Tel Aviv University, and a Master of Science degree in Analytical Chemistry and Bachelor of Science Honors in Chemistry from the University of Cape Town in South Africa.
Avigail Glass
Administration Manager
Avigail Glass serves as Pharma Two B's Administration Manager & CEO assistance as of July 2008. Prior to working at pharma Two B Avigail served as an Executive Assistant & Administration Manager at DeveloGen Israel & Intel Israel.
Dan Teleman
MSc, MBA - CEO
Dan Teleman has been Pharma Two B’s CEO since May 23 and was previously the company’s President and brings over 20 years of experience in the biotechnology industry. Dan also serves as a Board member of 4C Biomed, an early stage immune-oncology company developing a novel antibody. Prior to joining Pharma Two B, Dan was an Executive Partner at Israel Biotech Fund, a life science VC. Dan was Chairman of Tamarix Pharma, an early stage ophthalmology company developing novel anti apoptotic molecules. Prior to that, Dan was the CEO of Atox Bio, where he led the company through an NDA submission for Reltecimod, the first immunomodulator developed for NSTI. Previously, Dan was the co-founder and CEO of PainReform (Nasdaq: PRFX), head of business development for Pharmos (Nasdaq: PARS) and held marketing and sales roles at Amgen. Dan is experienced in company formation, growth and fund raising. Dan holds an MBA from Duke University, Fuqua School of Business, and an MSc in Biochemical engineering from the Ben Gurion University.
Irit Zalayet
CPA, M.A. in Law - CFO
Ms. Zalayet CPA serves as Pharma Two B’s CFO as of September 2010. Prior to this Ms. Zalayet served as deputy CEO of Kesselman & Kesselman Trust Co. (1971) Ltd. and as a CPA at PwC Israel. Irit completed her Bachelors in Economics and Accounting and her M.A. in Law; both degrees are from The Bar- Ilan University. Ms. Zalayet also serves as the CFO of Stem Cell Medicine.
Hadas Friedman
MSc - VP Regulatory Affair & QA
Ms. Friedman serves as Pharma Two B’s VP QA, RA and Clinical Affairs since 2013. Prior to this Ms. Friedman served as the VP QA, RA and Clinical Affairs at Intec Pharma from 2004. Previous companies include Procognia and Rafa Laboratories. Hadas has completed a Bachelors of Science and a Masters of Science at the Bar-Ilan University.
Pninit Litman
PhD - VP Clinical Operations
Dr. Litman, serves as Pharma Two B's head of pharmacology and clinical studies since 2008. Prior to this Dr. Litman served as head of biology at Develogen Israel LTD and Peptor LTD where she gained extensive experience in investigational new drug development. Dr. Litman received her B.Sc. in microbiology from the Hebrew University of Jerusalem , Ph.D. in neurobiology from Weizmann Institute of Science and completed her post-doctoral training at Stanford University Medical Center, in USA.
Danny Fishelovitch
PhD - Head of CMC
Dr. Danny Fishelovitch has over 15 years of experience in the pharmaceutical industry. He Headed the Chemistry, Manufacturing and Controls (CMC) at several Biotech companies including Enlivex Therapeutics, Mitoconix Bio and Neuroderm that was acquired by Mitsubishi Tanabe Pharma group. Prior to that, Danny was a CMC leader and a lead formulator at Teva pharmaceuticals Ltd. Innovative R&D. Danny had also founded DFarma consulting and provides CMC consulting services for Biopharma companies. Danny specializes in the development of various sterile and solid dosage forms as well as drug device combination dealing with small molecules, Biopharmaceuticals such as peptides and proteins and cell based advanced therapeutic medicinal products (ATMPs). In addition, Danny has extensive experience in the development, scale-up and optimization of manufacturing processes by applying Quality-by-Design methodology. Danny was involved in clinical development plans (early POC to late-stage phase III) and in marketing regulatory applications. Danny is a pharmacist and computer scientist by training and holds a Ph.D. in Structural Biology from the Tel-Aviv University. He is an author of eight published scientific papers.
Corinne Zollmann
PhD - CMC Consultant
Dr. Corinne Zollmann has over 30 years of experience in the pharmaceutical industry, and is currently supporting biotechnology companies by providing Chemistry, Manufacturing, and Controls (CMC) consulting services. Her prior roles include SVP of CMC at both Tamarix Pharma and at Atox Bio, where she was responsible for the CMC Modules of the Reltecimod NDA submission. Prior to that she served as Senior Director of CMC at Chiasma and spent more than 20 years in numerous leadership positions at Teva Pharmaceutical’s Global Innovative R&D Division, including as Director of the CMC Program for Small Molecules. During that time, she gained broad experience in global development of innovative pharmaceutical drug products, including CMC management and development, validation, technology transfer, risk management, regulatory strategy and initiatives, and professional CMC project evaluation and due diligence. Corinne holds a PhD in Electrochemistry from the Tel Aviv University, and a Master of Science degree in Analytical Chemistry and Bachelor of Science Honors in Chemistry from the University of Cape Town in South Africa.
Cheryl Fitzer-Attas
PhD, MBA - Head of Medical Affairs
Dr. Cheryl Fitzer-Attas has >20 years of experience in the life sciences industry, with a clinical focus on neurological indications. Today, Cheryl is President of ClinMed LLC, where she works with several companies as Senior Advisor for clinical and medical affairs. Previously, Cheryl was Senior Medical Director at Mitsubishi Tanabe Pharma America, where she established the US and global medical affairs roadmaps for a new drug-device treatment for Parkinson’s disease. Before that, Cheryl was Vice President Clinical Research at CHDI, a not-for-profit research organization dedicated to acceleration of treatments for Huntington’s disease. Previously, at Teva Pharmaceuticals Industries, Cheryl was Global Medical Director for the Parkinson’s disease drug Azilect, where she played a pivotal role in the scientific communication of Azilect’s clinical trial data, including presentation and moderation at a public FDA Advisory Committee meeting. Dr. Fitzer-Attas has a B.Sc. in biology from the Hebrew University of Jerusalem, a Ph.D. in cell biology from the Weizmann Institute of Science, an MBA in marketing from Reichmann University, and she completed post-doctoral trainings at both the Weizmann Institute of Science and the University of California, San Francisco.
Avigail Glass
Administration Manager
Avigail Glass serves as Pharma Two B's Administration Manager & CEO assistance as of July 2008. Prior to working at pharma Two B Avigail served as an Executive Assistant & Administration Manager at DeveloGen Israel & Intel Israel.